Equitable Trust Co. Sells 7,811 Shares of Kenvue Inc. (NYSE:KVUE)

Equitable Trust Co. trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 30.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,534 shares of the company’s stock after selling 7,811 shares during the quarter. Equitable Trust Co.’s holdings in Kenvue were worth $374,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of KVUE. AMF Tjanstepension AB increased its stake in shares of Kenvue by 187.3% during the third quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock valued at $2,787,000 after purchasing an additional 78,540 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Kenvue by 371.7% in the 3rd quarter. Exchange Traded Concepts LLC now owns 29,887 shares of the company’s stock worth $691,000 after buying an additional 23,551 shares during the last quarter. Cornell Pochily Investment Advisors Inc. bought a new position in Kenvue during the 3rd quarter valued at approximately $215,000. Vontobel Holding Ltd. increased its position in Kenvue by 13.4% during the 3rd quarter. Vontobel Holding Ltd. now owns 22,594 shares of the company’s stock valued at $523,000 after buying an additional 2,677 shares in the last quarter. Finally, LaFleur & Godfrey LLC boosted its holdings in Kenvue by 12.5% in the third quarter. LaFleur & Godfrey LLC now owns 62,650 shares of the company’s stock worth $1,449,000 after acquiring an additional 6,985 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $20.93 on Wednesday. The firm has a market capitalization of $40.13 billion, a P/E ratio of 39.49, a PEG ratio of 2.16 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The business has a fifty day moving average of $21.46 and a 200 day moving average of $22.02.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.92%. Kenvue’s payout ratio is presently 154.72%.

Analyst Ratings Changes

Several brokerages have recently weighed in on KVUE. UBS Group reduced their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Bank of America boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.